 The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite PACC, in amyloid-positive participants who are asymptomatic at risk for developing Alzheimers dementia. 